Patent Expiries in the US Statin Market: Generics to Slash Market Size by 80 per Cent over the Next Ten Years

Abstract

References

Scandinavian Simvastatin Survival Study Group (1994). Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344(1), 383–389.

West of Scotland Coronary Prevention Group (1996). West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials, Lancet, 348(1), 339–342.

Cholesterol Treatment Trialists' (CTT) Collaborators (2005). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366(1), 267–278.

Nissen

Tuzcu

E.M.

Schoenhagen

Brown

B. G.

Ganz

Vogel

R.A.

Crowe

Howard

Cooper

C.J.

Brodie

Grilles

C.L.

De Maria

A.N.

(2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial, JAMA, 291, 1071–1080.

PCMA press release; February 3, 2006.

Pfizer press release; April 19, 2006.

Cowen & Company (July 17, 2006) Weekly new Rx trend summary: week ending July 7, 2006.

Bear Stearns & Company (July 24, 2006) Pfizer Inc. (PFE) US Equity Research.

DMHC208 (December 21, 2005) Commercial Insight: Antihypertensives — two years to shape the market?.

10.